Merck splits Human Health into two units as it braces for Keytruda's 2028 patent expiration. The $30B drug represents half of revenue.

Merck Splits Pharma Division as $30B Keytruda Cliff Looms

Merck beats Q4 with EPS $2.04 but guides 2026 below Street at $5-$5.15. Gardasil down 39% as China shipments halted. Keytruda hits $31.7B.

Merck Beats Q4 Estimates But Guides Low as Gardasil Headwinds Persist

Merck abandons $28-32B Revolution Medicines bid after price disagreement. RVMD stock crashes 22% as pivotal cancer drug data looms.

Merck Walks Away From $30 Billion Revolution Medicines Deal; Stock Plunges 22%

Merck bids $28-32B for Revolution Medicines, 40-60% above AbbVie's reported offer. Largest pharma deal since Pfizer-Seagen as Keytruda's 2028 patent cliff looms.

Merck & Co. (MRK)·Earnings Reports

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Analyst Coverage

Recent News about Merck & Co.

Merck Splits Pharma Division as $30B Keytruda Cliff Looms

Merck Beats Q4 Estimates But Guides Low as Gardasil Headwinds Persist

Merck Walks Away From $30 Billion Revolution Medicines Deal; Stock Plunges 22%

Merck Emerges as Lead Suitor for Revolution Medicines at $28-32 Billion

Patient Deaths Halt Merck's $5.5 Billion ADC Trial: Second Major Blow to Daiichi Partnership